On January 3, Glonghui reported that Neumora Therapeutics (NMRA.US) plummeted 81.42% overnight, followed by an 8.12% increase in after-hours trading, closing at $2.13. Regarding the news, the company announced on Thursday that its experimental drug for treating severe depression showed no efficacy in the final stage of research, as patients receiving navacaprant treatment did not exhibit significant improvements in depression symptom measurements statistically. Neumora is conducting two additional final phase trials for this drug and is developing other medications for brain disorders. (Glonghui)
美股异动丨Neumora夜盘涨超8% 忧郁症实验药物最后阶段研究失败
U.S. stocks fluctuate丨Neumora surged over 8% in after-hours trading after a failure in the final stage of its experimental depression medication research.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.